Healthcare

Drug protein discovery company Bright Peak hopes to deliver conjugated cancer immunotherapies based on an ETH Zürich-invented platform.

University of Louisville, University of Kentucky and Kentucky Science and Technology will extend their tech transfer expertise to other local institutions.

Co-founded by faculty from Columbia University and University of Melbourne, Praxis Precision Medicines targets CNS disorders.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Enthera Pharmaceuticals was co-founded by faculty from University of Milan and is using stem cells to treat autoimmune disorders.

CureVac has filed for an initial public offering in the US, 20 years after being spun out of Eberhard Karls University of Tübingen.

Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.